PipelineReview.com7h
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
NEW YORK, NY, USA I October 10, 2024 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) ...
PipelineReview.com7h
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
October 10, 2024 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
PipelineReview.com7h
Novo Holdings Launches Portfolio Company Booster Therapeutics to Advance New Class of Small Molecule Proteasome Activator Therapeutics
COPENHAGEN, Denmark I October 10, 2024 I Novo Holdings, a leading global life sciences investor, today announced the launch of Booster Therapeutics (Booster / the Company), a biotechnology company ...
PipelineReview.com16h
Novavax’s Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
GAITHERSBURG, MD, USA I October 9, 2024 I Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-Mâ„¢ adjuvant, today ...
PipelineReview.com17h
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients
BEIJING, China I October 09, 2024 I InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...
PipelineReview.com16h
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models of TH2 diseases ...
PipelineReview.com1d
City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine
Harnessing next-generation siRNA engineering to improve and expand the therapeutic reach of RNAi-based medicines ...
PipelineReview.com1d
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of PT886 in Combination with KEYTRUDA® (pembrolizumab)
SAN DIEGO, CA, USA I October 8, 2024 I Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and ...
PipelineReview.com1d
Blue Earth Therapeutics Advances Clinical Development of Lutetium (177Lu) rhPSMA-10.1 Injection with Promising Phase 1 Data
OXFORD, UK I October 8, 2024 I Blue Earth Therapeutics Ltd, an emerging leader in the development of therapeutic radiopharmaceuticals, today announced ...
PipelineReview.com1d
U.S. Food and Drug Administration (FDA) accepts New Drug Application for elinzanetant
BERLIN, Germany I October 09, 2024 I Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application ...
PipelineReview.com1d
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
PHILADELPHIA, PA, USA I October 08, 2024 I GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III ...
PipelineReview.com1d
Boehringer Ingelheim and Circle Pharma announce new research collaboration to develop a novel precision cancer treatment
INGELHEIM, Germany and SOUTH SAN FRANCISCO, CA, USA I October 09, 2024 I Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration ...